

David S. Perlin, Ph.D.

Dr. David Perlin is a highly accomplished biomedical researcher, senior administrator and recognized leader in combatting antibiotic and antifungal drug resistance. He is the inaugural Chief Scientific Officer for the Hackensack Meridian Health Center for Discovery and Innovation (CDI)(www.hmh-cdi.org), which was developed as an entrepreneurial research enterprise to rapidly translate innovations in science to improve outcomes for patients with cancer, infectious diseases, diabetes and other acute and chronic diseases and conditions. Dr. Perlin has been engaged for more than 30 years in developing molecular insights and technologies to detect, combat and prevent high-threat bacterial, fungal and viral infections. He has helped develop novel therapeutics and diagnostics, some of which are commercial products, and established a wide range of domestic and global programs addressing both hospital- and community-associated infections.

Dr. Perlin has written or co-authored more than 285 articles, chapters and books. His laboratory has been supported by multiple grants from the NIH, DoD, Pharma, biotechnology and foundation sectors. He has attracted more than \$110 million in grant funds. The NIH has continuously funded him for 30+ years and he leads an NIH-designated national Center of Excellence in Translational Research (CETR) to discover novel antibiotics against drug resistant bacterial infections. He also leads three other NIH sponsored antibiotic discovery programs to develop novel antibiotics against Gram negative drug resistant threats, as well as an NIH funded program examining genetic factors contributing to the emergence of multidrug resistance among major fungal pathogens. His group has developed novel diagnostics for outbreaks of the *Bacillus anthracis*, SARS-CoV-1, COVID-19, 2009 H1N1 flu, *Exserohilum rostratum*, *Candida auris*, *MDR-TB*, *KPCs* and other drug resistant bacterial and fungal pathogens. His group has worked closely with CDC, foreign governments and foundations, local and state health departments and area hospitals. Most recently, his group established the first FDA EUA-approved molecular diagnostic for SARS-CoV-2 for a hospital network; they helped develop and implement a highly successful high-titer convalescent plasma therapy program, and they are working closely with Pharma and Biotech partners to develop new drugs against SARS-CoV-2.

Prior to joining the CDI, he served for nearly two decades as Executive Director of the Rutgers New Jersey Medical School's Public Health Research Institute (PHRI), a 80-year-old specialized center for global infectious diseases. He was also Director of the Rutgers Regional Biocontainment Laboratory (RBL), one of thirteen NIH-designated national centers for high-threat biosafety level 3 pathogen research, and a Professor of Microbiology, Biochemistry and Molecular Genetics. As Executive Director, he led a research enterprise that attracted more than \$200 million in research support and \$100 million in licensing revenue.

Dr. Perlin has served on advisory boards for the NIH, foundations like the Bill & Melinda Gates Foundation, and numerous Pharma, biotech and diagnostic companies for development of novel therapeutics and diagnostics. He is a member of the Board of Directors of the Aaron Diamond AIDS Research Center (ADARC), and Scientific/Medical Advisory Boards including the Clinical Laboratory Standards Institute (CLSI) Antifungal sub-committee. He serves on numerous science editorial boards. Dr. Perlin is a Fellow of the American Academy of Microbiology (2018) and the New York Academy of Sciences (2006). He was named by RO1 a top 10 influencer in healthcare in New Jersey in 2019 and 2020; and 2020 Outstanding Scientist in New Jersey, as part of the Edward J. III Excellence in Medicine Awards. He is frequently in the news and his work on plasma therapy was recently profiled by *60 Minutes* (May 31, 2020).

PROFILE

- Chief Scientific Officer, Center for Discovery and Innovation (CDI), Hackensack Meridian *Health*
- Professor, Hackensack Meridian School of Medicine at Seton Hall
- Professor Emeritus, Infectious Diseases, Rutgers University, New Jersey Medical School
- Fellow, American Academy of Microbiology
- Fellow, New York Academy of Sciences

EDUCATION

- Ph.D., Plant Physiology, Cornell University, Ithaca, New York, 1980

POST-DOCTORATE

- Biochemistry/Genetics, Yale University School of Medicine, New Haven, Connecticut, 1983
- Biochemistry, University of Rochester School of Medicine and Dentistry, Rochester, New York, 1985

PROFESSIONAL

- 1985-1988 Assistant Member, Public Health Research Institute, New York, NY 1989-1991 Associate Member, Public Health Research Institute, New York, NY
- 1992-2018 Member, Public Health Research Institute, New York, NY
- 1992-2002 Adjunct Associate Professor, New York University School of Medicine, New York, NY
- 2005-2006 President, Public Health Research Institute, Newark, NJ
- 2006-2018 Executive Director, Public Health Research Institute, NJ Med Sch-UMDNJ, Newark, NJ
- 2009-2018 Director, Rutgers Regional Biocontainment Laboratory
- 2002-2018 Professor, Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ
- 2019- Professor Emeritus, Infectious Diseases, Rutgers Biomedical and Health Sciences, Newark, NJ
- 2019- Chief Scientific Officer & Senior Vice President, Hackensack Meridian Health Center for Discovery and Innovation, Nutley, NJ
- 2019- Professor, Department of Medical Sciences, Hackensack Meridian School of Medicine
- 2019- Member, Georgetown Lombardi Comprehensive Cancer Center Consortium

CONTACT

David S. Perlin, Ph.D.

Center for Discovery and Innovation- Hackensack Meridian *Health*

111 Ideation Way, Nutley, NJ 07110

Tel: 201-880-3100 (o)

Email: david.perlin@hmh-cdi.org;

Website: <https://hmh-cdi.org/>